Pirfenidone limits the progression of malignancy and slows the development of fibrosis in experimental hepatocarcinoma.
Introduction and Objectives: Hepatocarcinoma (HCC) is the fourth cause of cancer death in Mexico, derived from fibrotic, metabolic and inflammatory alterations, modifiable by pirfenidone (PFD), which has shown beneficial effects at these levels. Our aim is to demonstrate the hepatoprotection of PFD...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2025-04-01
|
| Серии: | Annals of Hepatology |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S1665268125000213 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|